Table 5 Univariable analysis of relapse-free survival
Whole cohort (n = 61) | ER positive patients (n = 50) | |||||||
|---|---|---|---|---|---|---|---|---|
Characteristics | Event/at risk (% survival) | Log rank P | HR | 95% CI | Event/at risk (% survival) | Log rank P | HR | 95% CI |
Pre-operative randomization | ||||||||
Fasting | 2/35 (94) | 0.049 | 1 | 1/29 (97) | 1 | |||
Carbohydrates | 6/26 (77) | 4.4 | 0.9 to 21.7 | 6/21 (71) | 0.012 | 9.3 | 1.1 to 77.7 | |
Nodal status | ||||||||
N0 | 3/43 (93) | 1 | 3/33 (91) | 1 | ||||
N+ | 5/18 (13) | 0.03 | 9.8 | 1.10 to 88.1 | 4/17 (77) | 0.16 | 2.8 | 0.63 to 12.6 |
Tumor size | ||||||||
T1 | 3/45 (93) | 1 | 3/39 (92) | 1 | ||||
T2 | 5/16 (69) | 0.009 | 5.5 | 1.3 to 23.2 | 4/11 (64) | 0.008 | 6.0 | 1.3 to 27.0 |
Nottingham gradeb | 0.33 | 0.31 | ||||||
Grade 1 | 0/11 (100) | 1 | 0/11 (100) | 1 | ||||
Grade 2 | 5/30 (83) | – | Inf. | Inf. | 5/30 (83) | Inf. | Inf. | |
Grade 3 | 3/20 (85) | – | inf. | Inf. | 2/9 (78) | inf. | Inf. | |
Estrogen receptor | – | – | – | – | ||||
Positive (≥ 1%) | 7/50 (86) | 1 | – | – | – | – | ||
Negative (< 1%) | 1/11 (91) | 0.67 | 1.6 | 0.2 to 12.7 | – | – | – | – |
Progesterone receptor | ||||||||
Positive (≥10%) | 4/41 (37) | 1 | 3/37 (92) | 1 | ||||
Negative (< 10%) | 4/20 (80) | 0.27 | 2.1 | 0.5 to 8.6 | 4/13 (69) | 0.048 | 4.0 | 0.90 to 18.1 |
HER2 | ||||||||
Negative (0 to 1+) | 7/57 (88) | 1 | 6/49 (88) | 1 | ||||
Positive (2+ to 3+) | 1/4 (75) | 0.46 | 2.1 | 0.3 to 17.5 | 1/1 (0) | 0.005 | 11.7 | 1.3 to 105.1 |
MAI | ||||||||
< 10 | 5/41 (88) | 1 | 4/39 (90) | 1 | ||||
≥ 10 | 3/19 (66) | 0.66 | 1.4 | 0.3 to 5.8 | 3/10 (70) | 0.09 | 3.4 | 0.8 to15.2 |
MAI | ||||||||
< 3 | 2/16 (88) | 1 | 2/16 (88) | 1 | ||||
≥ 3 | 6/44 (86) | 0.89 | 1.1 | 0.2 to 5.5 | 5/33 (85) | 0.80 | 1.2 | 0.2 to 6.4 |
PPH3 | ||||||||
< 13 | 3/35 (91) | 1 | 3/35 (91) | 1 | ||||
≥ 13 | 5/26 (81) | 0.26 | 2.2 | 0.5 to 9.4 | 4/15 (73) | 0.12 | 3.1 | 0.7 to 14.0 |
Ki67 | ||||||||
< 15 | 0/26 (100) | 0/25 (100) | 1 | |||||
≥ 15 | 8/34 (77) | 0.008 | – | – | 7/24 (71) | 0.003 | a | a |
Ki67 | ||||||||
< 30 | 3/38 (92) | 1 | 3/37 (92) | 1 | ||||
≥ 30 | 5/22 (77) | 0.093 | 3.2 | 0.8 to 13.4 | 4/12 (67) | 0.023 | 4.8 | 1.1 to 21.8 |
TILs | ||||||||
Negative (< 10%) | 2/13 (85) | 7/55 (87) | 1 | |||||
Positive (≥10%) | 6/48 (88) | 0.77 | 1.4 | 0.2 to 3.9 | 1/6 (83) | 0.75 | 2.2 | 0.24 |
Luminal statusc | ||||||||
Luminal A | 3/39 (92) | 2/28 (93) | ||||||
Luminal B | 5/22 (77) | 0.091 | 3.2 | 0.77 to 13.5 | 5/22 (77) | 0.11 | 3.5 | 0.68 to 18.1 |
Chemotherapy | ||||||||
Yes | 6/29 (79) | 1 | 5/20 (75) | 1 | ||||
No | 2/32 (94) | 0.096 | 0.28 | 0.06 to 1.4 | 2/30 (93) | 0.069 | 0.25 | 0.05 to 1.3 |
Radiotherapy | ||||||||
Yes | 6/43 (86) | 1 | 5/38 (87) | 1 | ||||
No | 2/17 (88) | 0.90 | 0.91 | 0.18 to 4.5 | 2/12 (83) | 0.72 | 1.4 | 0.26 to 7.0 |
Endocrine Therapy | ||||||||
Yes | 7/39 (82) | 1 | 6/36 (83) | 1 | ||||
No | 1/22 (96) | 0.15 | 0.24 | 0.03 to 2.0 | 1/14 (93) | 0.38 | 0.40 | 0.05 to 3.3 |
BMI-25d | ||||||||
< 25 | 3/31 (90) | 1 | 3/26 (89) | 1 | ||||
≥ 25 | 4/23 (83) | 0.40 | 1.9 | 0.42 to 8.4 | 3/20 (85) | 0.70 | 1.4 | 0.28 to 6.8 |
BMI-75pe | ||||||||
< 75p | 4/41 (90) | 1 | 4/36 (89) | 1 | ||||
≥ 75p | 3/13 (77) | 0.201 | 2.57 | 0.57 to 11.5 | 2/10 (80) | 0.417 | 1.99 | 0.36 to 10.9 |
Smoking | ||||||||
-Never smoked | 4/15 (73) | 1 | 3/12 (87) | 1 | ||||
-Former smoker | 1/23 (96) | 0.22 | 0.025 to 2.00 | 1/20 (95) | 0.26 | 0.027 to 2.5 | ||
-Ongoing smoking | 1/14 (93) | 0.065 | 0.14 | 0.015 to 1.22 | 1/12 (92) | 0.15 | 0.17 | 0.017 to 1.6 |